IMMUNITYBIO, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
IMMUNITYBIO, INC. (IBRX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$230.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-04
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$230.39M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$632.80M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$61.96M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$67.27M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$351.47M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$413.64M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$583.85M.
- IMMUNITYBIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$417.32M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$230.39M 10-Q · filed 2026-08-04 | -$863.19M 10-Q · filed 2026-08-04 | -$925.14M derived: sum of 3 quarters · filed 2026-08-04 | -$992.42M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$632.80M 10-Q · filed 2026-08-04 | -$694.75M derived: sum of 2 quarters · filed 2026-08-04 | -$762.03M derived: sum of 3 quarters · filed 2026-08-04 | -$854.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$61.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$129.23M derived: sum of 2 quarters · filed 2026-02-23 | -$221.81M derived: sum of 3 quarters · filed 2026-08-04 | -$351.47M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$67.27M 10-Q · filed 2025-11-05 | -$159.85M derived: sum of 2 quarters · filed 2026-08-04 | -$289.51M 10-Q · filed 2025-11-05 | -$348.69M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$92.57M 10-Q · filed 2026-08-04 | -$222.24M 10-Q · filed 2026-08-04 | -$281.42M derived: sum of 3 quarters · filed 2026-08-04 | -$367.17M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$129.67M 10-Q · filed 2026-08-04 | -$188.84M derived: sum of 2 quarters · filed 2026-08-04 | -$274.60M derived: sum of 3 quarters · filed 2026-08-04 | -$409.18M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2024-12-31 | -$59.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$144.93M derived: sum of 2 quarters · filed 2026-02-23 | -$279.51M derived: sum of 3 quarters · filed 2026-02-23 | -$413.64M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$85.75M 10-Q · filed 2025-11-05 | -$220.34M derived: sum of 2 quarters · filed 2025-11-05 | -$354.47M 10-Q · filed 2025-11-05 | -$587.88M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | -$134.58M 10-Q · filed 2025-11-05 | -$268.71M 10-Q · filed 2025-08-05 | -$502.13M derived: sum of 3 quarters · filed 2026-02-23 | -$597.77M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | -$134.13M 10-Q · filed 2025-11-05 | -$367.54M derived: sum of 2 quarters · filed 2026-02-23 | -$463.19M derived: sum of 3 quarters · filed 2026-02-23 | -$601.40M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | -$233.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$329.06M derived: sum of 2 quarters · filed 2026-02-23 | -$467.27M derived: sum of 3 quarters · filed 2026-02-23 | -$583.85M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$95.64M 10-Q · filed 2024-11-12 | -$233.85M derived: sum of 2 quarters · filed 2024-11-12 | -$350.44M 10-Q · filed 2024-11-12 | -$458.76M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$138.21M 10-Q · filed 2024-11-12 | -$254.80M 10-Q · filed 2024-08-12 | -$363.12M derived: sum of 3 quarters · filed 2025-03-03 | -$474.28M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$116.58M 10-Q · filed 2024-11-12 | -$224.91M derived: sum of 2 quarters · filed 2025-03-03 | -$336.07M derived: sum of 3 quarters · filed 2025-03-03 | -$430.90M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$108.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$219.49M derived: sum of 2 quarters · filed 2025-03-03 | -$314.32M derived: sum of 3 quarters · filed 2025-03-03 | -$417.32M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$111.16M 10-Q · filed 2023-11-09 | -$206.00M derived: sum of 2 quarters · filed 2023-11-09 | -$308.99M 10-Q · filed 2023-11-09 | -$400.55M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | -$94.83M 10-Q · filed 2023-11-09 | -$197.83M 10-Q · filed 2023-08-08 | -$289.39M derived: sum of 3 quarters · filed 2024-03-19 | -$377.81M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | -$103.00M 10-Q · filed 2023-11-09 | -$194.55M derived: sum of 2 quarters · filed 2024-03-19 | -$282.98M derived: sum of 3 quarters · filed 2024-03-19 | -$372.37M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | -$91.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$179.98M derived: sum of 2 quarters · filed 2024-03-19 | -$269.37M derived: sum of 3 quarters · filed 2024-03-19 | -$349.85M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | -$88.43M 10-Q · filed 2022-11-09 | -$177.81M derived: sum of 2 quarters · filed 2022-11-09 | -$258.30M 10-Q · filed 2022-11-09 | -$326.87M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-06-30 | -$89.39M 10-Q · filed 2022-11-09 | -$169.87M 10-Q · filed 2022-08-08 | -$238.44M derived: sum of 3 quarters · filed 2024-03-19 | -$304.61M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-03-31 | -$80.48M 10-K · filed 2024-03-19 | -$149.05M derived: sum of 2 quarters · filed 2024-03-19 | -$215.22M derived: sum of 3 quarters · filed 2024-03-19 | -$267.24M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2020-12-31 | -$68.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$134.74M derived: sum of 2 quarters · filed 2023-03-01 | -$186.76M derived: sum of 3 quarters · filed 2023-03-01 | -$224.19M 10-K · filed 2023-03-01 | -$92.38M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$66.17M 10-Q · filed 2021-11-12 | -$118.19M derived: sum of 2 quarters · filed 2021-11-12 | -$155.61M 10-Q · filed 2021-11-12 | -$60.25M 10-Q · filed 2020-11-09 | -$265.62M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$52.02M 10-Q · filed 2021-08-12 | -$89.44M 10-Q · filed 2021-08-12 | -$38.48M 10-Q · filed 2020-08-07 | -$199.45M derived: sum of 3 quarters · filed 2022-03-01 | -$215.03M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | -$37.43M 10-Q · filed 2021-05-14 | -$18.38M 10-Q · filed 2020-05-11 | -$147.44M derived: sum of 2 quarters · filed 2022-03-01 | -$163.02M derived: sum of 3 quarters · filed 2022-03-01 | -$179.70M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$110.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$125.59M derived: sum of 2 quarters · filed 2022-03-01 | -$142.27M derived: sum of 3 quarters · filed 2022-03-01 | -$160.16M 10-K · filed 2022-03-01 | -$65.79M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | -$15.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$32.26M derived: sum of 2 quarters · filed 2020-11-09 | -$50.15M 10-Q · filed 2020-11-09 | -$67.49M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | -$16.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$34.57M 10-Q · filed 2020-08-07 | -$51.91M derived: sum of 3 quarters · filed 2021-03-04 | -$75.54M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | -$17.89M 10-Q · filed 2020-05-11 | -$35.23M derived: sum of 2 quarters · filed 2021-03-04 | -$58.86M derived: sum of 3 quarters · filed 2021-03-04 | -$86.59M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | -$17.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$40.98M derived: sum of 2 quarters · filed 2021-03-04 | -$68.71M derived: sum of 3 quarters · filed 2021-03-04 | -$96.23M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | -$23.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$51.37M derived: sum of 2 quarters · filed 2019-11-05 | -$78.89M 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | -$27.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$55.25M 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | -$27.52M 10-Q · filed 2019-05-08 | |||||||
| 2017-12-31 | -$96.42M 10-K · filed 2020-03-25 | |||||||
| 2016-12-31 | -$120.81M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |